Reading this on a mobile device? Try our optimized mobile version here:

November 20, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
  • HIV screening urged for everyone aged 15 to 65 in U.S.
    The U.S. Preventive Services Task Force on Monday called for routine HIV testing for all Americans aged 15 to 65, expanding its 2005 recommendation that included only high-risk individuals. The draft recommendation was prompted by studies showing major health benefits of early HIV treatment, task force chairwoman Dr. Virginia Moyer said. USA Today (11/19) LinkedInFacebookTwitterEmail this Story
Announcing the Arrival of FMH RapidScreen from Immucor
The new FMH RapidScreen offers a faster more simplified feto-maternal hemorrhage screening test to give you peace of mind in generating a quick result for the protection of mothers and their newborns. FMH RapidScreen provides up to 35% decrease in total test time compared to other marketed tests. To learn more about this product, call us at 855-IMMUCOR or visit our website.

  Science & Health 
  • Experimental myeloma drug aids survival in trial
    Patients with multiple myeloma who received Celgene's pomalidomide plus low-dose dexamethasone lived significantly longer and had greater progression-free survival than those who received high-dose dexamethasone alone during a trial. An FDA review of the drug is expected to be completed by Feb. 10. Reuters (11/19) LinkedInFacebookTwitterEmail this Story
  Emerging Trends 
  Industry News & Practice 
  • Living Cell Technologies to start human Ntcell trial
    New Zealand's health regulators have given the go-ahead for Living Cell Technologies' early-stage clinical study of its Ntcell treatment for Parkinson's disease. The first human trial for the treatment is slated to start early next year. The therapy includes the transplantation of animal choral plexus cells into the brain to restore nerves. Australian Life Scientist (11/16) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • FDA OKs use of platelet drug to help hepatitis C patients
    The FDA approved GlaxoSmithKline and Ligand Pharmaceuticals' eltrombopag to treat low platelet count in people with hepatitis C so they can receive standard treatment. The approval is the first for supportive care to help patients unsuited for interferon-based therapy because of low platelet counts. Reuters (11/19) LinkedInFacebookTwitterEmail this Story
  Association News 
  • AABB requests nominations for 2013, 2014 Memorial Awards
    AABB is seeking nominations for its 2013 and 2014 Memorial Awards, which will honor individuals who have advanced the practice of transfusion medicine and cellular therapies. The awards are presented to recognize achievements in administration, immunohematology, quality and innovative research, and overall outstanding service. Individuals are encouraged to nominate candidates by completing and submitting the online nomination form by Jan. 25. Recipients will be honored at the 2013 AABB Annual Meeting in Denver or the 2014 AABB Annual Meeting in Philadelphia. LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
VP Patient ServicesBlood Centers of the PacificUS - CA - San Francisco
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Help Desk SpecialistAABBUS - MD
Click here to view more job listings.

A good man with a good conscience doesn't walk so fast."
--Georg Büchner,
German writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information